- Home
- RIGL vs AUTL Comparison
RIGL vs AUTL Comparison
Compare RIGL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- AUTL
- Stock Information
- Founded
- RIGL 1996
- AUTL 2014
- Country
- RIGL United States
- AUTL United Kingdom
- Employees
- RIGL N/A
- AUTL N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIGL Health Care
- AUTL Health Care
- Exchange
- RIGL Nasdaq
- AUTL Nasdaq
- Market Cap
- RIGL 334.5M
- AUTL 359.3M
- IPO Year
- RIGL 2000
- AUTL 2018
- Fundamental
- Price
- RIGL $18.28
- AUTL $1.22
- Analyst Decision
- RIGL Buy
- AUTL Strong Buy
- Analyst Count
- RIGL 5
- AUTL 5
- Target Price
- RIGL $36.40
- AUTL $9.32
- AVG Volume (30 Days)
- RIGL 205.1K
- AUTL 2.4M
- Earning Date
- RIGL 05-06-2025
- AUTL 05-08-2025
- Dividend Yield
- RIGL N/A
- AUTL N/A
- EPS Growth
- RIGL N/A
- AUTL N/A
- EPS
- RIGL 2.08
- AUTL N/A
- Revenue
- RIGL $203,077,000.00
- AUTL $9,011,000.00
- Revenue This Year
- RIGL $24.45
- AUTL $277.74
- Revenue Next Year
- RIGL $7.23
- AUTL $221.89
- P/E Ratio
- RIGL $8.77
- AUTL N/A
- Revenue Growth
- RIGL 70.16
- AUTL N/A
- 52 Week Low
- RIGL $7.48
- AUTL $1.11
- 52 Week High
- RIGL $29.82
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- RIGL 47.44
- AUTL 41.28
- Support Level
- RIGL $17.65
- AUTL $1.15
- Resistance Level
- RIGL $19.75
- AUTL $1.44
- Average True Range (ATR)
- RIGL 1.46
- AUTL 0.12
- MACD
- RIGL -0.02
- AUTL 0.00
- Stochastic Oscillator
- RIGL 16.39
- AUTL 21.21
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.